Eli Lilly and Company and AC Immune have signed an agreement for the research and development of tau aggregation inhibitor small molecules, and AC Immune signed a strategic partnership with WuXi biologics.
Researchers are using artificial intelligence to catalyze drug discovery and preclinical drug development - improving predictive models to guide efficient design and optimizing multi-drug regimens, as two recent examples.
Exelixis has submitted an investigational new drug application
(IND) to the US Food and Drug Administration (FDA) for XL820, a
novel small molecule anticancer compound that inhibits receptor
tyrosine kinases (RTKs) implicated in tumour...